Family · Pharmaceutical analytical standards
Vibegron
A selective beta-3 adrenergic agonist for overactive bladder, which relaxes the bladder muscle and increases its capacity; approved in Japan in 2018, in the United States in 2020 and in Europe in 2024. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?The suffix -begron unites the beta-3 adrenergic agonists: the family also includes mirabegron, the first of the class to be approved.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
